Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults Elisabetta Patorno, Ajinkya Pawar, Lily G. Bessette, Dae H. Kim, Chintan Dave, Robert J. Glynn, Medha N. Munshi, Sebastian Schneeweiss, Deborah J.
AbstractThe glucose portal sensor informs the brain of changes in glucose inflow through vagal afferents that require an activated glucagon-like peptide 1 receptor (GLP-1r). The GLP-1 system is known to be impaired in insulin-resistant conditions, and we sought to understand
AbstractActivation of the mineralocorticoid receptor (MR) may promote dysfunctional adipose tissue in patients with type 2 diabetes, where increased pericellular fibrosis has emerged as a major contributor. The knowledge of the association among the MR, fibrosis, and the effects of
AbstractBACKGROUND Long-term glycemic control reduces retinopathy risk, but transient worsening can occur with glucose control intensification. Glucagon-like peptide 1 receptor agonists (GLP-1RA) lower glucose, but the long-term impact on retinopathy is unknown. GLP-1RA cardiovascular outcome trials (CVOTs) provide long-term follow-up,
Generation of RORα MKO MiceWe generated mice harboring a floxed allele of Rora (Rorafl/fl) by flanking exon 3 with two loxP sequences. The strategy and outcome on RORα1 and RORα4 are summarized in figures S1A and S1B respectively. Briefly, a
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases Yan Xie, Benjamin Bowe, Andrew K. Gibson, Janet B. McGill, Geetha Maddukuri, Yan Yan,
AbstractLow-dose interleukin-2 (IL-2) represents a new therapeutic approach to regulate immune homeostasis to promote immune tolerance in patients with autoimmune diseases, including type 1 diabetes. We have developed a new IL-2–based biologic, an IL-2/CD25 fusion protein, with greatly improved pharmacokinetics
AbstractLoss-of-function mutations in both alleles of the human insulin receptor gene (INSR) cause extreme insulin resistance (IR) and usually death in childhood, with few effective therapeutic options. Bivalent antireceptor antibodies can elicit insulin-like signaling by mutant INSR in cultured cells,
AbstractSkeletal muscle insulin resistance is a prominent early feature in the pathogenesis of type 2 diabetes. In attempt to overcome this defect, we generated mice overexpressing insulin receptors (IR) specifically in skeletal muscle (IRMOE). On normal chow, IRMOE mice have
After learning that certain representative immunoblot images in the above-cited paper may have been duplicated, the authors have decided to voluntarily retract the article. The potential duplications occur in the following images:The myocyte panels for GRK2 and β-actin in Fig.